Home » Newsletters » BioWorld Science

BioWorld Science

July 24, 2006

View Archived Issues

Fluoglizine more potent than fluoxetine in a mouse model of depression/anxiety

Neuroprotective effects of RWJ-333369 shown in a rat status epilepticus model

Emisphere and Roche establish multiproduct research collaboration

Inex to complete spin-out of Tekmira in September

Russian sites cleared to participate in BiovaxID phase III study

Xceleron to conduct phase 0 microdose study for Biofrontera Bioscience

Nerviano Medical Sciences to scale up Indena compounds

DNAPrint Genomics signs research agreement with Beth Israel Deaconess

DAC selects Evotec as partner for Hsp90 discovery project

ProtoKinetix' AAGP protects cells while preserving normal cell function

Alteon shareholders approve HaptoGuard merger

ImClone and Merck amend and supplement Erbitux agreement

New phase II study evaluates HGS-ETR1 with bortezomib in multiple myeloma

AVI BioPharma modifies HCV study of AVI-4065

CF-101 begins phase IIb for rheumatoid arthritis

CellTran and Innogenetics negotiate combining wound care activities

Nikken Chemical launches Selenica R tablet 400 mg in Japan

New glia-targeting clinical candidate presented with efficacy in AD

Nexavar approved in Europe for advanced renal cell carcinoma

New agents for treating neurological disorders disclosed in recent patent literature

Novel therapeutic agents for metabolic disorders reported

Symbicort receives FDA approval

New TGF-beta antagonists prepared and tested by Korean scientists

Tysabri available in U.S. for relapsing MS

TaiGen Biotechnology reports initial preclinical data of its novel agent against SARS virus

Tygacil now available in U.K.

Lansoprazole in chronic postnasal drip to be evaluated in clinical study / News in Context

Important antinociceptive actions of PPC-5383, a novel acid-sensing ion channel blocker

Promising preclinical results of novel Abeta fibril-disrupting agents developed at ProteoTech

Protective effects of dactylorhin B against beta amyloid-induced brain mitochondrial toxicity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...